Skip to main content
Finanzoo GmbH Finanzoo GmbH

Alkermes Value Stock - Dividend - Research Selection

Alkermes

ISIN: IE00B56GVS15 , WKN: A1JKVH
Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company\'s marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

2026-04-14
— 56-Week Post Hoc Analysis Demonstrated Sustained Reduction in Hard-to-Treat Negative Symptoms —...
Finnhub

Preparation is key to understanding global trade compliance for trials

2026-04-13
Matthew Leets, head of global trade compliance at Alkermes, discusses the complexities of shipping investigational products in global trials.
Yahoo

B of A Securities Maintains Neutral on Alkermes, Raises Price Target to $36

2026-04-09
B of A Securities analyst Jason Gerberry maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $34 to $36.
Benzinga

Alkermes Starts Phase 3 Orexin Trials As Narcolepsy Story Builds

2026-04-02
Alkermes (NasdaqGS:ALKS) has started Phase 3 Brilliance Studies for alixorexton, an orexin 2 receptor agonist for narcolepsy type 1 and 2. The program builds on the drug's breakthrough therapy designation and moves it into late stage clinical testing. The news follows increased sector attention after Eli Lilly acquired a company with competing orexin receptor drug candidates. For investors watching Alkermes, the move into Phase 3 comes as the share price sits at $35.05, with the stock up...
Yahoo

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

2026-04-01
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset. The following five companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline builders that could diversify ... These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
Yahoo

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

2026-04-01
DUBLIN, April 01, 2026--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, NT2 and idiopathic hypersomnia (IH).
Yahoo

Top 2 Health Care Stocks That May Implode In April

2026-04-01
Health care stocks warning for momentum investors. RSI indicator used to predict short term performance. Alkermes & Assertio overbought.
Benzinga

Alkermes Initiates Brilliance Studies Phase 3 Program Of Alixorexton For Adults With Narcolepsy Type 1 and Type 2

2026-04-01
Alkermes plc (NASDAQ:ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and
Benzinga

Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest

2026-04-01
Alkermes PLC (NASDAQ:ALKS) is one of the 10 Stocks Dominating Today’s Market Surge. Alkermes extended gains for a second day on Tuesday to nearly hit its 52-week high, as investors digested the growing interest in the orexin receptor agonist market following a pharmaceutical giant’s official foray into the sector. Weight loss drugmaker Eli Lilly and […]
Yahoo

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

2026-03-31
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave Life, Perimeter Solutions, Praxis Precision, and Century Aluminum.
Benzinga